Clinical, toxicological and pharmacological aspects of gemcitabine
- 1 January 1996
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 22 (1), 15-31
- https://doi.org/10.1016/s0305-7372(96)90014-6
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Non-Small-Cell Lung CarcinomaDrugs, 1995
- Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cAnnals of Oncology, 1994
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neckAnnals of Oncology, 1994
- Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trials GroupAnnals of Oncology, 1994
- Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)Annals of Oncology, 1994
- Kinetic studies on 2',2'-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminaseBiochemical Pharmacology, 1993
- Activity of 2, 2 -difluorodeoxycytidine (Gemcitabine) against human tumor colony forming unitsAnti-Cancer Drugs, 1992
- Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cellsAnti-Cancer Drugs, 1991
- Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabineCancer Chemotherapy and Pharmacology, 1991